Robinul Forte

See also: Generic Robinul

Robinul Forte is a brand name of glycopyrrolate, approved by the FDA in the following formulation(s):

ROBINUL FORTE (glycopyrrolate - tablet; oral)

• 
  Manufacturer: SHIONOGI INC
  
  Approved Prior to Jan 1, 1982
  
  Strength(s): 2MG ^[RLD][AA]

Has a generic version of Robinul Forte been approved?

A generic version of Robinul Forte has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Robinul Forte and have been approved by the FDA:

glycopyrrolate tablet; oral

• 
  Manufacturer: BOCA PHARMA
  
  Approval date: October 19, 2011
  
  Strength(s): 2MG ^[AA]


• 
  Manufacturer: COREPHARMA
  
  Approval date: December 22, 2004
  
  Strength(s): 2MG ^[AA]


• 
  Manufacturer: DR REDDYS LABS LTD
  
  Approval date: March 21, 2008
  
  Strength(s): 2MG ^[AA]


• 
  Manufacturer: PAR PHARM
  
  Approval date: August 31, 2006
  
  Strength(s): 2MG ^[AA]


• 
  Manufacturer: RANBAXY
  
  Approval date: August 18, 2009
  
  Strength(s): 2MG ^[AA]


• 
  Manufacturer: VINTAGE
  
  Approval date: December 29, 2008
  
  Strength(s): 2MG ^[AA]


• 
  Manufacturer: WEST WARD
  
  Approval date: March 5, 2009
  
  Strength(s): 2MG ^[AA]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Robinul Forte. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Method for increasing the bioavailability of glycopyrrolate
  Patent 7,091,236
  Issued: August 15, 2006
  Inventor(s): Roberts; Alan & Venkataraman; Bala
  Assignee(s): Sciele Pharma, Inc.
  The invention relates to a method of increasing the bioavailability of glycopyrrolate by administration of a therapeutically effective amount of glycopyrrolate without food.
  
  Patent expiration dates:
  
  
  • April 24, 2024
    
    ✓ 
    Patent use: FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PEPTIC ULCER
  
  

See also...

• Robinul Forte Consumer Information (Wolters Kluwer)
• Robinul Forte Consumer Information (Cerner Multum)
• Robinul Forte Advanced Consumer Information (Micromedex)
• Glycopyrrolate Consumer Information (Wolters Kluwer)
• Glycopyrrolate Solution Consumer Information (Wolters Kluwer)
• Glycopyrrolate Tablets Consumer Information (Wolters Kluwer)
• Glycopyrrolate Consumer Information (Cerner Multum)
• Glycopyrrolate Advanced Consumer Information (Micromedex)
• Glycopyrrolate AHFS DI Monographs (ASHP)